Advertisement

Topics

Evotec AG: LAB282 Accelerates with Second Round Funding

02:26 EDT 22 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
* The drug discovery partnership between Oxford University, Evotec and Oxford Sciences Innovation Awards five new life sciences projects Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today t...

Other Sources for this Article

Oxford University Innovation
Gregg Bayes-Brown
Marketing and Communications Manager,
T: +44 (0)1865 280867
E: gregg.bayes-brown@innovation.ox.ac.uk
or
Evotec AG
Gabriele Hansen
VP Corporate Communications & Investor Relations
Phone: +49.(0)40.56081-255
gabriele.hansen@evotec.com

NEXT ARTICLE

More From BioPortfolio on "Evotec AG: LAB282 Accelerates with Second Round Funding"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...